報價延遲最少15分鐘:2026/04/25 01:16 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
11.26 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
0.72/6.50
|
|
企業價值
10.87B
|
| 資產負債 |
|
每股賬面淨值
2.89
|
| 現金流量 |
|
現金流量率
0.31
|
| 損益表 |
|
收益
6.22B
|
|
每股收益
23.63
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments. |
